Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / KNTE - Kinnate Biopharma begins dosing in phase 1 trial of KIN-3248 in advanced tumors

KNTE - Kinnate Biopharma begins dosing in phase 1 trial of KIN-3248 in advanced tumors

Kinnate Biopharma Inc.
Kinnate Biopharma (NASDAQ:KNTE) said the first patient began treatment in a phase 1 trial of KIN-3248 in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations. The company is exploring KIN-3248 as a next-generation pan-FGFR inhibitor for treating intrahepatic cholangiocarcinoma (ICC) (bile-duct cancer) and urothelial carcinoma (UC) (bladder cancer), and other solid tumors. The phase 1 trial, dubbed KN-4802, is a two-part study in ~120 patients. The dose expansion phase (Part B) will evaluate KIN-3248 at recommended dose in FGFR inhibitor naïve and FGFR inhibitor pretreated patients with cancers driven by FGFR2 and/or FGFR3 gene alterations, including ICC, UC and other selected adult solid tumors.

For further details see:

Kinnate Biopharma begins dosing in phase 1 trial of KIN-3248 in advanced tumors
Stock Information
Company Name: Kinnate Biopharma Inc.
Stock Symbol: KNTE
Market: NASDAQ
Website: kinnate.com
Menu
KNTE KNTE Quote KNTE Short KNTE News KNTE Articles KNTE Message Board
Get KNTE Alerts

News, Short Squeeze, Breakout and More Instantly...